BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18308439)

  • 21. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety.
    Beitelshees AL; McLeod HL
    Trends Pharmacol Sci; 2006 Sep; 27(9):498-502. PubMed ID: 16876261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics, ethics, and public policy.
    Peterson-Iyer K
    Kennedy Inst Ethics J; 2008 Mar; 18(1):35-56. PubMed ID: 18561577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Orphan drugs in France (2001-2005): access to information and characteristics].
    Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
    Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Technological advances in mucositis research: new insights and new issues.
    Gibson RJ; Bowen JM; Keefe DM
    Cancer Treat Rev; 2008 Aug; 34(5):476-82. PubMed ID: 18358615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantifying emerging drugs for very rare conditions.
    Miles KA; Packer C; Stevens A
    QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Orphan diseases].
    Loizzo A; Tebano MT
    Recenti Prog Med; 1993 Nov; 84(11):786-93. PubMed ID: 8290793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The coming pharmacogenomics revolution: tailoring drugs to fit patients' genetic profiles.
    Noah L
    Jurimetrics; 2002; 43(1):1-28. PubMed ID: 17333591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare.
    Shah J
    Nat Biotechnol; 2003 Jul; 21(7):747-53. PubMed ID: 12833092
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics.
    Almarsdóttir AB; Björnsdóttir I; Traulsen JM
    Health Policy; 2005 Feb; 71(2):233-41. PubMed ID: 15607385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lost in translation.
    Butler D
    Nature; 2007 Sep; 449(7159):158-9. PubMed ID: 17851509
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of health technology assessment in the comprehensive evaluation of the impact of immunotherapy on real practice.
    Frati F; Ariano R; Cadario G; Ortolani C; Passalacqua G
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():4-6. PubMed ID: 18924459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Apr; 73(68):19074-6. PubMed ID: 18677821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.